Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of chrysophanol in preparation of medicine for treating pulmonary arterial hypertension

A technology of pulmonary arterial hypertension and chrysophanol, which is applied in the field of biomedicine, can solve the problems of unseen pulmonary arterial hypertension, poor treatment effect, and many adverse reactions, and achieves the advantages of reducing pulmonary vascular remodeling, high safety, and reducing right ventricular hypertrophy. Effect

Active Publication Date: 2022-01-28
DALIAN MEDICAL UNIVERSITY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Combination therapy is also regarded as the standard treatment for PAH, but the current clinical drugs are still limited, and the treatment effect is poor, and there are many adverse reactions. There is an urgent need for drugs with better efficacy and safety.
However, there is no research report on its use in pulmonary arterial hypertension

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chrysophanol in preparation of medicine for treating pulmonary arterial hypertension
  • Application of chrysophanol in preparation of medicine for treating pulmonary arterial hypertension
  • Application of chrysophanol in preparation of medicine for treating pulmonary arterial hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The application of embodiment 1 chrysophanol in the treatment of pulmonary hypertension

[0023] 1. Animals and experimental reagents:

[0024] Mice (strain: strain: Kunming mice, purchased from SPF Animal Experiment Center, Institute of Genome Engineering Model Animals for Major Diseases, Dalian Medical University)

[0025] 2. Establishment of hypoxia-induced pulmonary hypertension model:

[0026] Twenty-four healthy Kunming male mice (body weight 20-25 grams) were randomly divided into two groups according to the principle of body weight balance, namely the experimental group and the control group. The mice in the control group were reared in a standard aseptic feeding environment, and were randomly divided into two groups according to the principle of body weight balance, namely the normoxia + solvent group (the same volume of solvent as the chrysophanol group, intraperitoneal injection method) and the normoxia + chrysophanol group. group (chrysophanol 25mg / kg / 2 da...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of chrysophanol in preparation of a medicine for treating pulmonary arterial hypertension. The invention belongs to the technical field of biological medicine. According to the invention, a pulmonary arterial hypertension disease mouse model is constructed through hypoxia (10%) induction. After chrysophanol is injected into the intraperitoneal cavity, the conditions of fur, diet, activity, death and the like of the pulmonary arterial hypertension mouse model are observed. Results show that chrysophanol (as shown in the formula I) has the effects of remarkably improving pulmonary vascular remodeling of animals with pulmonary hypertension, relieving right ventricular hypertrophy and right heart failure, improving the life quality of the animals with pulmonary hypertension (improving feeding and water inflow) and increasing the survival rate of the animals with pulmonary hypertension. Therefore, the chrysophanol has a wide application prospect in the aspect of preventing and treating the pulmonary arterial hypertension disease.

Description

technical field [0001] The present invention relates to a new application of chrysophanol (chrysophanol, 1,8-Dihydroxy-3-methyl-anthraquinone, 1,8-dihydroxy-3-methyl-anthraquinone), in particular to the preparation of chrysophanol for the treatment of pulmonary hypertension application in medicine. The invention belongs to the technical field of biomedicine. Background technique [0002] Pulmonary Artery Hypertension (PAH) is a highly malignant cardiovascular disease, which can be an independent disease or a complication or syndrome. Its pathological manifestations include persistent pulmonary vasoconstriction, vessel wall remodeling, and in situ thrombus formation, resulting in progressive pulmonary artery pressure elevation, right-sided heart failure and death. In the past 20 years, with the in-depth research on the etiology and pathogenesis of PAH, the survival time of patients after diagnosis has been extended from 2.8 years to more than 7 years, but the disease is sti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/122A61P9/12A61P11/00
CPCA61K31/122A61P9/12A61P11/00
Inventor 沈婷婷刘丕旭刘晓芳牛文慧黄丹
Owner DALIAN MEDICAL UNIVERSITY